The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Natural killer (NK) cells are an emerging cellular immunotherapy for patients with acute
myeloid leukemia (AML); however, the best approach to maximize NK cell antileukemia …

In recent years, our understanding of the molecular pathogenesis of myeloid neoplasms,
including acute myeloid leukemia (AML), has been greatly advanced by genomics discovery …

Abstract The revised 2017 European LeukemiaNet (ELN) recommendations for genetic risk
stratification of acute myeloid leukemia have been widely adopted, but have not yet been …

Background Many mutations that contribute to the pathogenesis of acute myeloid leukemia
(AML) are undefined. The relationships between patterns of mutations and epigenetic …

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many
cancers, including∼ 12% of acute myeloid leukemia (AML). In preclinical models these …

Acute myeloid leukemia (AML) is a heterogeneous clonal disorder characterized by
immature myeloid cell proliferation and bone marrow failure. Cytogenetics and mutation …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …